Shares of nano-cap company Minerva Neurosciences, Inc. (NERV) plunged over 60% on Tuesday morning after the company said it received a Complete Response Letter from the U.S. Food and Drug Administration for New Drug Application for Roluperidone for the treatment of negative symptoms in patients with schizophrenia.
NERV is currently trading at $2.6700, down $4.1300 or 60.74%, on the Nasdaq. The stock opened its trading at $3.3000 after closing Monday's trading at $6.8000. The stock has traded between $1.5000 to $13.4900 in the past 52-week period.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com